Lung CancersBLTNCT07064395
Bright Light Therapy on Sleep Health in Lung Cancer Patients
A study testing bright light in people with Lung Cancers, run by Henry Ford Health System at 1 site in United States.
Trial summary
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Lung Cancers
- What is being tested?
- bright light
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 6 participants
- Where
- 1 siteUnited States
- Study dates
- 9 Jun 2025to 31 Mar 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- >=18 years of age
- Stage Ib to IIIb primary lung cancer diagnosis
- >=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
- ECOG performance status is 0 or 1
- Experience problematic sleep (scores of >=8 on the Insomnia Severity Index)
- Able to understand, speak, and read English
- Sighted and mentally competent to consent
Who cannot join
- Pregnant women
- Have metastatic cancer
- on oxygen therapy
- Current diagnosis of seasonal affective disorder or substance abuse
- Engage in shift work or travel across >3 time zones within 2 weeks prior to the study
- Are currently being treated for sleep apnea, restless legs syndrome, or narcolepsy
Show all 10Show fewer
- Take prescribed sedative hypnotics or antipsychotics
- Have eye conditions (glaucoma or retinal disease), problem triggered by bright light (e.g., migraine), or take photosensitizing medications (e.g., some porphyrin drugs, antipsychotics, antiarrhythmic agents)
- Participants with an Insomnia Severity Index <8
- Participants with cognitive impairment (sores of <3 mini-cog test)
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Bright Light Therapy to Reduce Sleep Disturbance and Biological Aging in Lung Cancer Patients
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are:
- Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients?
- Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging.
Read more
Participants will:
- Receive bright light exposure or usual light exposure every day for 4 weeks
- Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests
- Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks
- Keep a daily sleep log
- Conditions
- Lung Cancers
- Being tested
- bright light
- Keywords
- bright light, intervention, biological age, sleep, lung cancer
- Medical subject headings
- Lung Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
bright lightOther
Lung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks.
| Study group | Role | What they receive |
|---|---|---|
| bright light arm | Experimental | Participants will receive a daily 30-minutes bright light through light visor for 4 weeks. Receives: Other: bright light |
| control arm | No intervention | Participants will not receive bright light, and keep their usual daily light exposure for 4 weeks. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change from Baseline in sleep patterns at 4 weeks
Changes in sleep patterns will be assessed by sleep efficiency (e.g., duration of sleep in hours), sleep quality (e.g., number of sleep disturbance), and sleep onset latency (e.g., minutes of falling asleep).
Measured: from enrollment to the end of the intervention at 4 weeks
Changes from baseline in the measures of biological age at 4 weeks
Participants have a lower rate of biological aging
Measured: From enrollment to the end of intervention at 4 weeks
Secondary outcomes (1)
Change from Baseline in the measure of fatigue and stress at 4 weeks
Participants will achieve a response if they have lower level of fatigue and stress level at 4 weeks. Stress will be assessed by stress scale ranging from 0 to 40, and a higher score refers to worse stress level. Fatigue will be assessed by a fatigue score ranging from 0-40, and a higher scale means severe fatigue level.
Measured: From enrollment to the end of intervention at 4 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted14 Jul 2025
- Study start9 Jun 2025
- Primary completion31 Mar 2026
- Study completion31 Mar 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Lung CancersStudies of the same condition, open and under way.
- More trials run by Henry Ford Health SystemThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 6 participants (actual)
Sponsor and investigators
- Lead sponsor
- Henry Ford Health System
- Sponsor type
- University, hospital or other
- Collaborators
- Michigan State University
- Responsible party
- Principal investigator, Menghua Tao, Henry Ford Health System
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07064395
- Sponsor's protocol ID
- 17849
- Other IDs
- F80046
- Acronym
- BLT
- Status last verified
- Jul 2026
- First submitted
- 25 Jun 2025
- Last updated
- 2 Jul 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 2 Jul 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Bright Light Therapy to Reduce Sleep Disturbance and Biological Aging in Lung Cancer Patients
- ClinicalTrials.gov ID
- NCT07064395
- Acronym / sponsor ID
- BLT / 17849
- Conditions
- Lung Cancers
- Keywords
- bright light, intervention, biological age, sleep, lung cancer
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 6 participants (actual)
- Lead sponsor
- Henry Ford Health SystemUniversity, hospital or other
- Collaborators
- Michigan State University
- Study start
- 9 Jun 2025 (actual)
- Primary completion
- 31 Mar 2026 (actual)
- Study completion
- 31 Mar 2026 (actual)
- First posted
- 14 Jul 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this randomized intervention trial is to determine the effect of bright light therapy on sleep disturbance, as well as to investigate the impacts of bright light therapy on biological age measured by clinical biomarkers. The main questions it aims to answer are:
- Does bright light therapy improve sleep patterns (i.e., sleep onset latency, sleep disturbance, and sleep efficiency) in lung cancer patients?
- Can bright light therapy slow the rate of aging measured by biological age in lung cancer patients? Researchers will compare bright light therapy group to control group to see if bright light works to reduce sleep disturbance and decelerate biological aging.
Participants will:
- Receive bright light exposure or usual light exposure every day for 4 weeks
- Get blood draw at the baseline and at 4 weeks for clinical biomarkers tests
- Complete self-reported sleep, fatigue and stress surveys at the baseline and at 4 weeks
- Keep a daily sleep log
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| bright light arm | Experimental | Other: bright lightParticipants will receive a daily 30-minutes bright light through light visor for 4 weeks. |
| control arm | No intervention | –Participants will not receive bright light, and keep their usual daily light exposure for 4 weeks. |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- >=18 years of age
- Stage Ib to IIIb primary lung cancer diagnosis
- >=2 months after completion of primary therapy, patient can continue to be on maintenance/immunotherapy
- ECOG performance status is 0 or 1
- Experience problematic sleep (scores of >=8 on the Insomnia Severity Index)
Key exclusion criteria (10 listed)
- Pregnant women
- Have metastatic cancer
- on oxygen therapy
- Current diagnosis of seasonal affective disorder or substance abuse
- Engage in shift work or travel across >3 time zones within 2 weeks prior to the study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| bright lightLung cancer patients in the bright light arm will receive 12,000 lux bright light through light visor for 4 weeks. | Other | bright light arm |
Primary outcome
Change from Baseline in sleep patterns at 4 weeks
Time frame: from enrollment to the end of the intervention at 4 weeks
Changes in sleep patterns will be assessed by sleep efficiency (e.g., duration of sleep in hours), sleep quality (e.g., number of sleep disturbance), and sleep onset latency (e.g., minutes of falling asleep).
Changes from baseline in the measures of biological age at 4 weeks
Time frame: From enrollment to the end of intervention at 4 weeks
Participants have a lower rate of biological aging
1 secondary outcome
Change from Baseline in the measure of fatigue and stress at 4 weeks
Time frame: From enrollment to the end of intervention at 4 weeks
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 2 Jul 2026.
Related trials for Lung Cancers
RecruitingPhase 1/2
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Solid Tumor, Non-Small Cell Lung Cancer
RecruitingObservational study
A Prospective ,Multicenter ,Non-interventional ,Real-world Study Observing Changes in Molecular Markers Osimertinib Targeted Therapy in EGFRm NSCLC
Non Small Cell Lung Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 3
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Non-Small Cell Lung Cancer (NSCLC)
Active, not recruitingPhase 2
Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer
Metastatic Lung Cancer, Advanced Non Small Cell Lung Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing bright light in people with Lung Cancers, run by Henry Ford Health System at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 2 Jul 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change from Baseline in sleep patterns at 4 weeks (time frame: from enrollment to the end of the intervention at 4 weeks). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 Jul 2026.